ClinConnect ClinConnect Logo
Search / Trial NCT01621594

Evaluating New Radiation Techniques for Cardiovascular Imaging

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Jun 14, 2012

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Computer Tomography Cardiac Radiation Reduction Iterative Reconstruction

ClinConnect Summary

This clinical trial is exploring new techniques for taking pictures of the heart and blood vessels using a special type of scan called computed tomography (CT). These new methods aim to reduce the amount of radiation exposure while still providing clear and accurate images. This is important for diagnosing conditions like coronary disease, which affects the heart and blood vessels.

To participate in the trial, you need to be an adult aged 18 or older who is scheduled for a CT scan to check for heart or blood vessel issues. Before the scan, the study team will review your medical history and perform a physical exam. You may receive a contrast agent during the scan to enhance the image quality, and the entire process could take up to two hours. After the scan, follow-up may be needed to discuss results or any further tests. If you're interested, you will have the chance to learn more and ask questions before deciding to participate.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • 1. Clinical indication for a coronary CT angiography exam
  • 2. Age equal to or greater than 18 years
  • 3. Able to understand and willing to sign the Informed Consent Form
  • 4. Able and willing to provide follow-up information
  • EXCLUSION CRITERIA:
  • 1. Pregnancy
  • 2. If receiving intravenous contrast, severe renal excretory dysfunction, estimated glomerular filtration rate \< 30 mL/min/1.73m2 body surface area according to the Modification of Diet in Renal Disease criteria or as reported by the clinical lab. Glomerular filtration rate will be estimated using the 2021 CK-EPI equation that eliminate the use of race coefficient as reported in CRIS.
  • Screen Failures: Subjects who are screen failures can be re-enrolled once they meet eligibility criteria. Rescreened participants will be assigned the same participant number as for the initial screening.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

Patients applied

MD

1 patients applied

Trial Officials

Marcus Y Chen, M.D.

Principal Investigator

National Heart, Lung, and Blood Institute (NHLBI)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials